1. Home
  2. ACET vs GEG Comparison

ACET vs GEG Comparison

Compare ACET & GEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.00

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

GEG

Great Elm Group Inc.

N/A

Current Price

$1.98

Market Cap

80.9M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ACET
GEG
Founded
1947
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
69.6M
80.9M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
ACET
GEG
Price
$7.00
$1.98
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$56.00
N/A
AVG Volume (30 Days)
111.8K
66.6K
Earning Date
03-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$1.76
52 Week High
$9.05
$3.51

Technical Indicators

Market Signals
Indicator
ACET
GEG
Relative Strength Index (RSI) 45.55 34.26
Support Level $6.54 N/A
Resistance Level $8.34 $2.20
Average True Range (ATR) 0.44 0.08
MACD -0.06 0.00
Stochastic Oscillator 17.94 14.27

Price Performance

Historical Comparison
ACET
GEG

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About GEG Great Elm Group Inc.

Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.

Share on Social Networks: